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I-14 Treatment of hepatitis B virus
M. Omata*. Department of Gastroenterology, University of
Tokyo, Japan
HBV was discovered in 1964 and HBV suppression by
treatment started in late 1970 by Dr. Greenberg using
Interferon. However, until 1998 when Dr. CL Lai reported
one year experience of Lamivudine in N Engl J Med, the
treatment of HBV has not become common practice. That
time, I wrote critical comment on this article by Editorial
in N Engl J Med (1998; 339: 114 5). Because the majority of
the patients treated had infection more than thirty years or
sometimes even ﬁfty years. And only one year suppression
is not obviously sufﬁcient to change the natural course of
HBV infection. Subsequently, very high resistance rate was
noted in the Lamivudine treatment and long-term efﬁcacy
was blurred.
And now, experiences of three to ﬁve years of drug use
were gathered and several drugs seem so far very safe and
potential suppressor of HBV replication for long time. Now
the question is raised how long it can continue to suppress
HBV before the emergence of HBV resistant mutant. In my
talk, I will compare the potency and durability of several
drugs and emergency of resistant strains. In addition, I
will address the validations of new APASL guideline by our
own patients’ data and on the Japanese experiences of
the improvement of liver history, treated by nucleoside
analogues for 3 years. We know envision the use of these
drugs for longer than ﬁve years. I personally feel if these
drugs can suppress longer than ten years, probably the
natural course of HBV infection could be drastically changed
in the majority of HBV carriers.
I-15 From the pathogenesis to the therapeutic strategy
of chronic hepatitis B infection
G.Q. Wang*. Department of Infectious Diseases & Center
for Liver Diseases, Peking University First Hospital, Beijing
100034, China
Chronic HBV infection is a severe public health problem in
the world, especially in China and Asia-Paciﬁc Area. Although
some new drugs developed in the treatment of chronic
hepatitis B, such as pegylated interferon, lamivudine,
adefovir, entecavir and telbivudine, not all the patients
beneﬁt from them, especially the sustain response is not
satisﬁed.
There are two main reasons for the HBV infection as an
intractable disease. One is the HBV cccDNA, the template
for the replication of virus, that no drugs have worked
on it. Another is the immune tolerance or dysfunction of
the host immune system on HBV. The ﬁnal elimination of
the HBV cccDNA depends upon the immune system, that
is, the viral speciﬁc cytotoxic T lymphocyte (CTL) and
cytokines contribute the sustain viral inhibition by inducing
the apoptosis of the viral infected hepatocytes, and the
exhaustion of the cccDNA reservoir by sustain inhibition of
the viral replication. So, immune modulation treatment that
can provoke the immune system will play a very important
role in the control of HBV infection.
As the sustain HBV inhibition rely on the immune system,
the immune modulatory agents should be considered as
the main therapeutic strategy of chronic HBV infection,
unfortunately, only interferon a including pegylated
interferon will be used in the young patients with low
level HBVDNA and elevated ALT, and Thymosin a1 can be
one of candidate as a immunomodulatory agent. As the
nucleos(t)ide acid has a strong potency of inhibiting the virus
but no immunomodulatory effect, the combination with two
type agents will be a potential strategy in the future. The
development of new agents with immunomodulatory effect
may change the outcome of chronic hepatitis B patients,
but there is a long way to go.
Concurrent Session 2 Bacterial infection
I-16 Prevalence of dupA of Helicobacter pylori strains
isolated from Shanghai patients and its clinical
implications
H. Lu*. Shanghai Renji Hospital afﬁliated to Shanghai Jiao
Tong University School of Medicine, Shanghai Institution of
Digestive Disease, Shanghai, China
Aims: To determine the prevalence of duodenal ulcer
promoting (dupA) gene of Helicobacter pylori in patients
with various gastroduodenal diseases in Shanghai and to
explore the association between the gene and other
putative virulence factors.
Methods: H. pylori were isolated from gastric biopsies of
patients with chronic gastritis, duodenal ulcer (DU), gastric
ulcer (GU), or non-cardia gastric carcinoma. The dupA,
cagA, vacA, iceA and babA2 genotypes were determined by
polymerase chain reaction. Histological features of gastric
mucosal biopsy specimens were graded based on the scoring
system proposed by the updated Sydney system.
Results: Isolates from 360 patients including 133 with
chronic gastritis, 101 with DU, 47 with GU, and 79 with
non-cardia gastric carcinoma were examined. The dupA
gene was detected in 35.3% (127/360) and the prevalence
DU patients was signiﬁcantly greater than that in gastric
cancer or GU patients (45.5% vs. 24.1% and 23.4%,
P < 0.05). Patients infected with dupA-positive strains had
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